OM1 Enters European Market to Enhance AI-Powered Real-World Evidence Solutions for Life Sciences
OM1, a leader in real-world data (RWD) and AI-driven insights for the life sciences industry, has announced its expansion into Europe. This strategic move aims to strengthen support for pharmaceutical and healthcare organizations by providing high-quality, AI-enhanced real-world evidence (RWE) solutions. By broadening its geographic reach, OM1 is poised to help life sciences companies generate actionable, data-driven insights that can improve patient outcomes, support regulatory decisions, and drive commercial success.
Addressing the Growing Demand for Real-World Evidence
The expansion comes in response to the increasing need for validated, AI-powered real-world data and robust observational research in Europe. As regulatory agencies, healthcare providers, and pharmaceutical companies increasingly rely on RWE to inform decision-making, OM1’s entry into the European market will provide critical support for global life sciences organizations. The company’s solutions will help in areas such as drug development, market access, and post-market surveillance, ensuring that evidence-based insights can be leveraged to enhance healthcare strategies.
Dr. Richard Gliklich, CEO and Founder of OM1, emphasized the significance of this move, stating, “OM1 has consistently been at the forefront of using AI to enrich real-world data and deliver meaningful, patient-centered insights. Expanding into Europe allows us to better serve our global customers by enabling them to generate critical real-world insights that improve patient outcomes and drive commercial success.”
Leveraging AI for Advanced Data Insights
OM1’s AI-driven platforms have revolutionized real-world evidence generation by enabling the extraction of deep disease insights, improving clinical development, and accelerating regulatory and market access efforts. A key component of OM1’s expansion strategy is the deployment of its OM1 Aspen platform, which supports both prospective and retrospective studies, as well as patient registries. This comprehensive approach allows for a more nuanced understanding of disease progression, treatment effectiveness, and patient outcomes.
Additionally, OM1’s digital phenotyping platform, PhenOM®, will play a critical role in advancing healthcare research in Europe. This platform utilizes AI and machine learning to analyze large-scale, real-world datasets, enabling life sciences organizations to refine clinical strategies and gain deeper insights into disease mechanisms. PhenOM® is particularly valuable for identifying patient subpopulations, optimizing therapeutic interventions, and addressing unmet medical needs.
Strengthening Collaborations with European Institutions
As part of its European expansion, OM1 plans to collaborate with leading healthcare institutions, regulatory agencies, and biopharmaceutical companies. These partnerships will facilitate the integration of OM1’s AI-powered solutions into European healthcare ecosystems, ensuring that real-world evidence is effectively utilized to support clinical innovation and policy development.
Eric Mertz, General Manager of OM1 Europe, highlighted the company’s commitment to addressing the unique challenges of the European market. “With the increasing demand for AI-driven real-world evidence solutions across Europe, OM1 is well-positioned to support life sciences organizations in navigating evolving regulatory frameworks and advancing research and commercialization. This expansion allows us to deliver tailored, region-specific solutions that offer greater insights and contribute to improved patient outcomes.”
Enhancing Regulatory and Market Access Strategies
Regulatory agencies across Europe, including the European Medicines Agency (EMA), are placing greater emphasis on the use of real-world evidence in decision-making. OM1’s expansion will allow pharmaceutical companies to better align with these evolving requirements by providing high-quality data insights that support regulatory submissions, health technology assessments, and reimbursement negotiations.
Through its AI-driven analytics and data integration capabilities, OM1 will help biopharmaceutical firms accelerate the approval process for new therapies, optimize post-market surveillance efforts, and demonstrate the real-world effectiveness of their products. These capabilities are particularly critical for companies developing treatments for rare diseases, where traditional clinical trials may be limited by small patient populations.
Addressing Unmet Medical Needs
One of the primary goals of OM1’s expansion into Europe is to address unmet medical needs by leveraging real-world data to inform treatment strategies. Many chronic and complex diseases require long-term management, and real-world evidence can provide invaluable insights into patient experiences, treatment adherence, and health outcomes.
By utilizing AI-driven analytics, OM1 aims to improve the understanding of disease patterns, identify emerging health trends, and support personalized medicine approaches. This data-driven approach will empower healthcare providers with the information needed to make more informed decisions, ultimately leading to better patient care and improved health outcomes.
Driving Innovation in the Life Sciences Sector
OM1’s expansion is expected to foster greater innovation in the European life sciences sector by providing pharmaceutical companies, healthcare providers, and researchers with access to state-of-the-art real-world data solutions. The integration of AI and machine learning into real-world evidence generation will not only enhance the accuracy of insights but also streamline the process of identifying novel treatment opportunities.
Moreover, OM1’s data-driven approach will support life sciences organizations in adapting to changing healthcare landscapes, including the shift towards value-based care models. By demonstrating the real-world impact of therapies, OM1’s solutions will help pharmaceutical companies and healthcare systems align treatment strategies with patient-centered outcomes.
